Evercore ISI Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $205.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by Evercore ISI from $191.00 to $205.00 in a report published on Tuesday morning, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

A number of other equities analysts have also commented on the stock. Wells Fargo & Company lowered their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research report on Wednesday, September 4th. Cantor Fitzgerald restated an overweight rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a buy rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. lowered their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a report on Wednesday, September 4th. Finally, Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a buy rating in a research note on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $193.77.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $151.26 on Tuesday. The stock has a market cap of $8.81 billion, a P/E ratio of -15.97 and a beta of 0.63. The company has a fifty day moving average price of $133.30 and a two-hundred day moving average price of $136.64. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its position in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after purchasing an additional 44,580 shares during the last quarter. Capital International Investors boosted its position in Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Ascendis Pharma A/S by 5.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after purchasing an additional 93,185 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.